The company has revised its FY27 revenue guidance to more than ₹660 crore, up from its earlier projection of ₹600 crore, reflecting management’s confidence in its expanding global opportunity pipeline, diversified business model and growing operating scale across business verticals.
Cupid attributed the stronger outlook to rising opportunities in international B2B healthcare markets, supported by institutional buyers, private-sector customers and government procurement programmes.
The company also highlighted the commencement of its long-term supply agreement with the Partnership for Supply Chain Management (PFSCM) in the Netherlands, which it believes will strengthen its position in global healthcare procurement.
Management also cited strong order visibility across private markets and international tenders, continued growth in its male and female condom businesses, increasing acceptance of its lubricant portfolio, and expanding opportunities in its consumer wellness business across modern trade, organised retail and pharmacy networks.
Capacity expansion, operational efficiencies and backward integration initiatives are also expected to support future growth and profitability.
Chairman and Managing Director Aditya Kumar Halwasiya said the strong start to FY27 reflects the transformation the company has undergone over the past few years, with multiple growth engines beginning to scale simultaneously. He added that the company expects profit margins to remain strong, aided by favourable USD-INR realisations and an improving pricing environment, while net profit margins are likely to exceed current guidance. Cupid also plans to operationalise its new Palava manufacturing facility in the coming quarter to further strengthen production capabilities.
Also Read: KPIT Tech warns of a weak Q1 but the Street may have had an inkling
The company added that its In Vitro Diagnostics (IVD) business remains a long-term opportunity, with management expecting the segment to become a meaningful contributor as regulatory approvals, product launches and commercialisation progress.
Ahead of the announcement, shares of Cupid Ltd settled 0.85% higher at ₹190 on the NSE.
